Coya Therapeutics’ investigational low-dose interleukin-2 (IL-2) for subcutaneous administration, COYA 301, has been found to increase Treg function and halt
Read more
According to a recent UK population-based study published in The Lancet, approximately one in ten individuals are now affected by
Read more
Chiesi Global Rare Diseases and Protalix BioTherapeutics, Inc. have received marketing authorization from the European Commission (EC) for their drug,
Read more
StemBioSys, Inc. (StemBioSys) announced on Monday, the launch of NeuroMatrix™, an astrocyte-derived extracellular matrix that is developed to enable the
Read more
The novel 3DProSeed ® StromaLine ® developed by Ectica is an advantageous collection of pre-developed and well characterized stromal models
Read more
A new Oxford-GSK Institute of Molecular and Computational Medicine will be established through a substantial five-year cooperation between GlaxoSmithKline plc
Read more
New Phase 3 Data has shown a positive correlation between the human monoclonal antibody ADUHELM™ treatment effect on biomarkers and
Read more
Genentech’s investigational antibody for the treatment of early-stage Alzheimer’s disease, Gantenerumab, has been granted Breakthrough Therapy Designation by the U.S.
Read more
The unique 3DProSeed® ready-to-use 96-well microtiter plate developed by Ectica Technologies contains pre-assembled synthetic hydrogels, ready for screening 3D cell
Read more
The cutting-edge multispectral tissue cytometry hardware TissueFAXS SPECTRA, developed by TissueGnostics, has the unique ability to enable multispectral imaging of
Read more